Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Status: Enrolling
Updated:  12/31/1969
Be Well Medical Center
mi
from
Berkley, MI
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Status: Enrolling
Updated: 12/31/1969
Be Well Medical Center
mi
from
Berkley, MI
Click here to add this to my saved trials
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Status: Enrolling
Updated:  12/31/1969
Central West Clinical Research
mi
from
Saint Louis, MO
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Status: Enrolling
Updated: 12/31/1969
Central West Clinical Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Status: Enrolling
Updated:  12/31/1969
Southwest CARE Center
mi
from
Santa Fe, NM
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Status: Enrolling
Updated: 12/31/1969
Southwest CARE Center
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Enhancing Quality Interventions Promoting Healthy Sexuality
Enhancing Quality Interventions Promoting Healthy Sexuality
Status: Enrolling
Updated:  12/31/1969
Boys & Girls Clubs of Greater Lee County
mi
from
Auburn, AL
Enhancing Quality Interventions Promoting Healthy Sexuality
Enhancing Quality Interventions Promoting Healthy Sexuality
Status: Enrolling
Updated: 12/31/1969
Boys & Girls Clubs of Greater Lee County
mi
from
Auburn, AL
Click here to add this to my saved trials
Enhancing Quality Interventions Promoting Healthy Sexuality
Enhancing Quality Interventions Promoting Healthy Sexuality
Status: Enrolling
Updated:  12/31/1969
Boys & Girls Clubs of North Alabama
mi
from
Huntsville, AL
Enhancing Quality Interventions Promoting Healthy Sexuality
Enhancing Quality Interventions Promoting Healthy Sexuality
Status: Enrolling
Updated: 12/31/1969
Boys & Girls Clubs of North Alabama
mi
from
Huntsville, AL
Click here to add this to my saved trials
Enhancing Quality Interventions Promoting Healthy Sexuality
Enhancing Quality Interventions Promoting Healthy Sexuality
Status: Enrolling
Updated:  12/31/1969
Boys & Girls Clubs of Montgomery
mi
from
Montgomery, AL
Enhancing Quality Interventions Promoting Healthy Sexuality
Enhancing Quality Interventions Promoting Healthy Sexuality
Status: Enrolling
Updated: 12/31/1969
Boys & Girls Clubs of Montgomery
mi
from
Montgomery, AL
Click here to add this to my saved trials
Enhancing Quality Interventions Promoting Healthy Sexuality
Enhancing Quality Interventions Promoting Healthy Sexuality
Status: Enrolling
Updated:  12/31/1969
Atlanta Boys and Girls Club
mi
from
Atlanta, GA
Enhancing Quality Interventions Promoting Healthy Sexuality
Enhancing Quality Interventions Promoting Healthy Sexuality
Status: Enrolling
Updated: 12/31/1969
Atlanta Boys and Girls Club
mi
from
Atlanta, GA
Click here to add this to my saved trials
Lactoferrin Treatment in HIV Patients
Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Lactoferrin Treatment in HIV Patients
Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men
Efficacy of Internet-based HIV Prevention
Status: Enrolling
Updated:  12/31/1969
Hunter College
mi
from
New York, NY
Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men
Efficacy of Internet-based HIV Prevention
Status: Enrolling
Updated: 12/31/1969
Hunter College
mi
from
New York, NY
Click here to add this to my saved trials
Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men
Efficacy of Internet-based HIV Prevention
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men
Efficacy of Internet-based HIV Prevention
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men
Efficacy of Internet-based HIV Prevention
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men
Efficacy of Internet-based HIV Prevention
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Brief Intervention for Rural Women at High Risk for HIV/HCV
Brief Intervention for Rural Women at High Risk for HIV/HCV
Status: Enrolling
Updated:  12/31/1969
Rural Appalachian Research Center
mi
from
Hazard, KY
Brief Intervention for Rural Women at High Risk for HIV/HCV
Brief Intervention for Rural Women at High Risk for HIV/HCV
Status: Enrolling
Updated: 12/31/1969
Rural Appalachian Research Center
mi
from
Hazard, KY
Click here to add this to my saved trials
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)
Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)
Status: Enrolling
Updated:  12/31/1969
Mattel Children's Hospital at UCLA
mi
from
Los Angeles, CA
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)
Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)
Status: Enrolling
Updated: 12/31/1969
Mattel Children's Hospital at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)
Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)
Status: Enrolling
Updated:  12/31/1969
Mark O. Hatfield Clinical Research Center, NIH
mi
from
Bethesda, MD
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)
Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)
Status: Enrolling
Updated: 12/31/1969
Mark O. Hatfield Clinical Research Center, NIH
mi
from
Bethesda, MD
Click here to add this to my saved trials
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Status: Enrolling
Updated:  12/31/1969
University of Minnesota, Division of Infectious Diseases
mi
from
Minneapolis, MN
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Status: Enrolling
Updated: 12/31/1969
University of Minnesota, Division of Infectious Diseases
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CD34+ Stem Cell Infusion to Augment Graft Function
Post Transplant CD34+ Selected Stem Cell Infusion to Augment Graft Function in Children With Primary Immunodeficiency Diseases and Bone Marrow Failure Syndromes
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
CD34+ Stem Cell Infusion to Augment Graft Function
Post Transplant CD34+ Selected Stem Cell Infusion to Augment Graft Function in Children With Primary Immunodeficiency Diseases and Bone Marrow Failure Syndromes
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Therapeutic Vaccine for HIV
A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Therapeutic Vaccine for HIV
A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Site
mi
from
Omaha, NE
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Granada Hills, CA
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Granada Hills, CA
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Irvine, CA
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Irvine, CA
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Redlands, CA
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Redlands, CA
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Centennial, CO
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Centennial, CO
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Roswell, GA
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Roswell, GA
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Springfield, IL
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Springfield, IL
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Wichita, KA
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Fort Mitchell, KY
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Fort Mitchell, KY
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Farmington Hills, MI
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Plymouth, MN
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Plymouth, MN
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
East Setauket, NY
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
East Setauket, NY
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
New York, NY
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
New York, NY
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Columbus, OH
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Mayfield Heights, OH
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Toledo, OH
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Toledo, OH
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Pawtucket, RI
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Pawtucket, RI
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Anderson, SC
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Anderson, SC
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Nashville, TN
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Amarillo, TX
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Amarillo, TX
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Dallas, TX
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Irving, TX
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Irving, TX
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Los Angeles, CA
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Fort Wayne, IN
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Chicago, IL
Octagam 5% Versus Comparator Post Marketing Trial
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of Ibudilast for Methamphetamine Dependence
Randomized Trial of Ibudilast for Methamphetamine Dependence
Status: Enrolling
Updated:  12/31/1969
UCLA Vine Street Clinic
mi
from
Los Angeles, CA
Trial of Ibudilast for Methamphetamine Dependence
Randomized Trial of Ibudilast for Methamphetamine Dependence
Status: Enrolling
Updated: 12/31/1969
UCLA Vine Street Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  12/31/1969
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 12/31/1969
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  12/31/1969
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 12/31/1969
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  12/31/1969
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 12/31/1969
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  12/31/1969
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 12/31/1969
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials